Organization (Other)
EUROFARMA LABORATORIOS S.A.
ClinicalTrials.gov lists EUROFARMA LABORATORIOS S.A. as lead sponsor of 64 trials. It has 78 active development programs and 22 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 10 registered with a 2026 start date. The dashed outline is the pace from the 7 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 4.0 trial starts a year over the five years to September, under the 5 a year the method needs. 5 trials are registered to start in 2027 or later.
This page covers EUROFARMA LABORATORIOS S.A.: 64 lead-sponsored trials and 1 legal-entity registration.
Disease areas (37)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Asthma | 5 |
| Rhinitis, Allergic | 5 |
| Diabetes Mellitus | 4 |
| Diabetes Mellitus, Type 2 | 4 |
| Pain | 4 |
Showing 5 of 37 disease areas.
Trials by start year as sponsor or collaborator (17)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 5 trials are registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 10 |
| 2025 | 6 |
| 2024 | 3 |
| 2023 | 3 |
| 2022 | 1 |
| 2020 | 2 |
| 2019 | 3 |
| 2018 | 1 |
| 2017 | 1 |
| 2016 | 2 |
Showing 10 of 17 years.
Recruitment duration, a model prediction: none of the 64 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (78)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Experimental drug | Acne Vulgaris | Phase 3 | 1 |
| N1087 | Alopecia | Phase 3 | 1 |
| Fluticasone 250mcg/Formoterol 12mcg/Glycopyrronium 25mcg | Pulmonary Disease, Chronic Obstructive | Phase 3 | 1 |
| Minoxidil oral solution | Alopecia | Phase 3 | 1 |
| Comparator - Trimbow® | Pulmonary Disease, Chronic Obstructive | Phase 3 | 1 |
Showing 5 of 78 active programs.
Approved assets (22)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Foradil | 3 |
| CISPLATIN | 3 |
| MOMETASONE FUROATE | 1 |
| Pregabalin | 1 |
| Zopiclone | 1 |
Showing 5 of 22 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 42% hit target (n=33) | 22% on time (n=18) |
Journals published in (7)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Advances in rheumatology (London, England) | 2 |
| Arquivos de gastroenterologia | 1 |
| Brazilian journal of otorhinolaryngology | 1 |
| Clinics (Sao Paulo, Brazil) | 1 |
| Diabetology & metabolic syndrome | 1 |
Showing 5 of 7 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 1 | 0 | 2014-05-06 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| VAI | 1 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 23 | 2026-02-20 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Eurofarma Laboratorios S/A | Itapevi, BR | FDA |
Latest dated events (90)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2027-05-31 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-01-31 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-01-30 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-01-30 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 90 events.
Biomarker capability evidence (68)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| CYP19A1 | Trial sponsor | Named in trial inclusion criteria |
| GLB1 | Trial sponsor | Primary endpoint in a Phase 3 trial |
| GLB1 | Trial sponsor | Primary endpoint in a Phase 3 trial |
| GPT | Trial collaborator | Named in trial inclusion criteria |
| HDLBP | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 68 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda recalls, climate targets, as filed, workforce and board diversity, as filed, organization relationships, clia clinical laboratory certificates, and biomarkers this organization publishes on.